QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA

QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA

Abstract OBJECTIVE Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy. The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China. In 2023 ASN...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-11, Vol.26 (Supplement_8), p.viii257-viii258
Hauptverfasser: Zheng, Haojie, Que, Tianshi, Yi, Guozhong, Li, Zhiyong, Qu, Shanqiang, Zhang, Peidong, Yuan, Xi, Wang, Yajuan, Liu, Junlu, Nan, Jing, Liu, Ting, Xu, Haiyan, Qi, Songtao, Huang, Guanglong
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page viii258
container_issue Supplement_8
container_start_page viii257
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 26
creator Zheng, Haojie
Que, Tianshi
Yi, Guozhong
Li, Zhiyong
Qu, Shanqiang
Zhang, Peidong
Yuan, Xi
Wang, Yajuan
Liu, Junlu
Nan, Jing
Liu, Ting
Xu, Haiyan
Qi, Songtao
Huang, Guanglong
description Abstract OBJECTIVE Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy. The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China. In 2023 ASNO we reported PFS.Now we reporte update about OS from our single center study. METHODS From January 2019 to December 2022, a total of 25 patients with newly diagnosed HGG (ndHGG) treated with TTFields were retrospectively included in our study. Among these patients, 9 patients received concurrent radiochemotherapy in combination with TTFields and 16 patients received non-concurrent chemoradiotherapy in combination with TTFields. The primary endpoint of the study was mPFS and mOS (Kaplan-Meier method used to estimate PFS and OS survival curves). Secondary endpoint was the influences about KPS score in PFS and OS. RESULTS The 25 ndHGG patients treated with TTFields included nine males and sixteen females with a mean age of 47.1 years (12-68). Gross total resection (GTR) was performed in eighteen patients. Twenty-one patients were IDH wild type, eleven patients showed methylation of the MGMT promoter. Followed up until January 2024, the median PFS was 13.3 months [95% CI: 11.33-15.2] with TTFields combined and 4.0 months (95% CI, 3.8-4.4) without TTFields treatment in EF-14.Median OS was 26.53 months [95% CI:19.47-33.57] with TTFields and 16.0 months (95% CI, 3.8-4.4) control in EF-14. In the KPS stratification, OS was 27.5 months (95% CI: 22.95-32.1) vs 4.3 months (95% CI: 0-11.2), p=0.0001. The OS of patients with concurrent chemoradiotherapy combined with TTFields vs. without concurrent chemoradiotherapy combined with TTFields was 26.5 months (95% CI: 24.33-28.7) vs 21.2 (95% CI: 3.1-39.3) months, p=0.59. CONCLUSIONS TTFields therapy is an effective treatment for HGG. In this study the addition of TTFields resulted in a statistically significant improvement in PFS and OS.
doi_str_mv 10.1093/neuonc/noae165.1019
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_neuonc_noae165_1019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noae165.1019</oup_id><sourcerecordid>10.1093/neuonc/noae165.1019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c839-ed9ec537e00359e80781585650181eb9f2d2333ef475b3da6772bcb46cd66933</originalsourceid><addsrcrecordid>eNqNkEtOwzAURS0EEqWwAiZvA27tuHbsodX8LKVOaYwYRvk4EgiaKlEH7J7-FsDoXT3dcwcHoVdKFpQottz747Bvl_uh9lTw04-qOzSjPGCYSyHuLznAktPwET1N0xchAeWCzlDzljuDyWoB79tIuxgKC5lJM5zudBRDmptio2GrnYmtK8Ht4lMpgg_jMnAuMXEelZDsig1YbRNtU8iKcmuczsFYWGfG6mf00Nffk3-53Tkqk9itM5wXqVnrHLeSKew75VvOQk8I48pLEkrKJRecUEl9o_qgCxhjvl-FvGFdLcIwaNpmJdpOCMXYHLHrajsO0zT6vjqMnz_1-FtRUp0lVVdJ1U1SdZZ0ohZXajge_gX8AYzxY5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA</title><source>Oxford Journals - Connect here FIRST to enable access</source><creator>Zheng, Haojie ; Que, Tianshi ; Yi, Guozhong ; Li, Zhiyong ; Qu, Shanqiang ; Zhang, Peidong ; Yuan, Xi ; Wang, Yajuan ; Liu, Junlu ; Nan, Jing ; Liu, Ting ; Xu, Haiyan ; Qi, Songtao ; Huang, Guanglong</creator><creatorcontrib>Zheng, Haojie ; Que, Tianshi ; Yi, Guozhong ; Li, Zhiyong ; Qu, Shanqiang ; Zhang, Peidong ; Yuan, Xi ; Wang, Yajuan ; Liu, Junlu ; Nan, Jing ; Liu, Ting ; Xu, Haiyan ; Qi, Songtao ; Huang, Guanglong</creatorcontrib><description>Abstract OBJECTIVE Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy. The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China. In 2023 ASNO we reported PFS.Now we reporte update about OS from our single center study. METHODS From January 2019 to December 2022, a total of 25 patients with newly diagnosed HGG (ndHGG) treated with TTFields were retrospectively included in our study. Among these patients, 9 patients received concurrent radiochemotherapy in combination with TTFields and 16 patients received non-concurrent chemoradiotherapy in combination with TTFields. The primary endpoint of the study was mPFS and mOS (Kaplan-Meier method used to estimate PFS and OS survival curves). Secondary endpoint was the influences about KPS score in PFS and OS. RESULTS The 25 ndHGG patients treated with TTFields included nine males and sixteen females with a mean age of 47.1 years (12-68). Gross total resection (GTR) was performed in eighteen patients. Twenty-one patients were IDH wild type, eleven patients showed methylation of the MGMT promoter. Followed up until January 2024, the median PFS was 13.3 months [95% CI: 11.33-15.2] with TTFields combined and 4.0 months (95% CI, 3.8-4.4) without TTFields treatment in EF-14.Median OS was 26.53 months [95% CI:19.47-33.57] with TTFields and 16.0 months (95% CI, 3.8-4.4) control in EF-14. In the KPS stratification, OS was 27.5 months (95% CI: 22.95-32.1) vs 4.3 months (95% CI: 0-11.2), p=0.0001. The OS of patients with concurrent chemoradiotherapy combined with TTFields vs. without concurrent chemoradiotherapy combined with TTFields was 26.5 months (95% CI: 24.33-28.7) vs 21.2 (95% CI: 3.1-39.3) months, p=0.59. CONCLUSIONS TTFields therapy is an effective treatment for HGG. In this study the addition of TTFields resulted in a statistically significant improvement in PFS and OS.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae165.1019</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii257-viii258</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Zheng, Haojie</creatorcontrib><creatorcontrib>Que, Tianshi</creatorcontrib><creatorcontrib>Yi, Guozhong</creatorcontrib><creatorcontrib>Li, Zhiyong</creatorcontrib><creatorcontrib>Qu, Shanqiang</creatorcontrib><creatorcontrib>Zhang, Peidong</creatorcontrib><creatorcontrib>Yuan, Xi</creatorcontrib><creatorcontrib>Wang, Yajuan</creatorcontrib><creatorcontrib>Liu, Junlu</creatorcontrib><creatorcontrib>Nan, Jing</creatorcontrib><creatorcontrib>Liu, Ting</creatorcontrib><creatorcontrib>Xu, Haiyan</creatorcontrib><creatorcontrib>Qi, Songtao</creatorcontrib><creatorcontrib>Huang, Guanglong</creatorcontrib><title>QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract OBJECTIVE Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy. The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China. In 2023 ASNO we reported PFS.Now we reporte update about OS from our single center study. METHODS From January 2019 to December 2022, a total of 25 patients with newly diagnosed HGG (ndHGG) treated with TTFields were retrospectively included in our study. Among these patients, 9 patients received concurrent radiochemotherapy in combination with TTFields and 16 patients received non-concurrent chemoradiotherapy in combination with TTFields. The primary endpoint of the study was mPFS and mOS (Kaplan-Meier method used to estimate PFS and OS survival curves). Secondary endpoint was the influences about KPS score in PFS and OS. RESULTS The 25 ndHGG patients treated with TTFields included nine males and sixteen females with a mean age of 47.1 years (12-68). Gross total resection (GTR) was performed in eighteen patients. Twenty-one patients were IDH wild type, eleven patients showed methylation of the MGMT promoter. Followed up until January 2024, the median PFS was 13.3 months [95% CI: 11.33-15.2] with TTFields combined and 4.0 months (95% CI, 3.8-4.4) without TTFields treatment in EF-14.Median OS was 26.53 months [95% CI:19.47-33.57] with TTFields and 16.0 months (95% CI, 3.8-4.4) control in EF-14. In the KPS stratification, OS was 27.5 months (95% CI: 22.95-32.1) vs 4.3 months (95% CI: 0-11.2), p=0.0001. The OS of patients with concurrent chemoradiotherapy combined with TTFields vs. without concurrent chemoradiotherapy combined with TTFields was 26.5 months (95% CI: 24.33-28.7) vs 21.2 (95% CI: 3.1-39.3) months, p=0.59. CONCLUSIONS TTFields therapy is an effective treatment for HGG. In this study the addition of TTFields resulted in a statistically significant improvement in PFS and OS.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkEtOwzAURS0EEqWwAiZvA27tuHbsodX8LKVOaYwYRvk4EgiaKlEH7J7-FsDoXT3dcwcHoVdKFpQottz747Bvl_uh9lTw04-qOzSjPGCYSyHuLznAktPwET1N0xchAeWCzlDzljuDyWoB79tIuxgKC5lJM5zudBRDmptio2GrnYmtK8Ht4lMpgg_jMnAuMXEelZDsig1YbRNtU8iKcmuczsFYWGfG6mf00Nffk3-53Tkqk9itM5wXqVnrHLeSKew75VvOQk8I48pLEkrKJRecUEl9o_qgCxhjvl-FvGFdLcIwaNpmJdpOCMXYHLHrajsO0zT6vjqMnz_1-FtRUp0lVVdJ1U1SdZZ0ohZXajge_gX8AYzxY5Q</recordid><startdate>20241111</startdate><enddate>20241111</enddate><creator>Zheng, Haojie</creator><creator>Que, Tianshi</creator><creator>Yi, Guozhong</creator><creator>Li, Zhiyong</creator><creator>Qu, Shanqiang</creator><creator>Zhang, Peidong</creator><creator>Yuan, Xi</creator><creator>Wang, Yajuan</creator><creator>Liu, Junlu</creator><creator>Nan, Jing</creator><creator>Liu, Ting</creator><creator>Xu, Haiyan</creator><creator>Qi, Songtao</creator><creator>Huang, Guanglong</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241111</creationdate><title>QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA</title><author>Zheng, Haojie ; Que, Tianshi ; Yi, Guozhong ; Li, Zhiyong ; Qu, Shanqiang ; Zhang, Peidong ; Yuan, Xi ; Wang, Yajuan ; Liu, Junlu ; Nan, Jing ; Liu, Ting ; Xu, Haiyan ; Qi, Songtao ; Huang, Guanglong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c839-ed9ec537e00359e80781585650181eb9f2d2333ef475b3da6772bcb46cd66933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Haojie</creatorcontrib><creatorcontrib>Que, Tianshi</creatorcontrib><creatorcontrib>Yi, Guozhong</creatorcontrib><creatorcontrib>Li, Zhiyong</creatorcontrib><creatorcontrib>Qu, Shanqiang</creatorcontrib><creatorcontrib>Zhang, Peidong</creatorcontrib><creatorcontrib>Yuan, Xi</creatorcontrib><creatorcontrib>Wang, Yajuan</creatorcontrib><creatorcontrib>Liu, Junlu</creatorcontrib><creatorcontrib>Nan, Jing</creatorcontrib><creatorcontrib>Liu, Ting</creatorcontrib><creatorcontrib>Xu, Haiyan</creatorcontrib><creatorcontrib>Qi, Songtao</creatorcontrib><creatorcontrib>Huang, Guanglong</creatorcontrib><collection>CrossRef</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Haojie</au><au>Que, Tianshi</au><au>Yi, Guozhong</au><au>Li, Zhiyong</au><au>Qu, Shanqiang</au><au>Zhang, Peidong</au><au>Yuan, Xi</au><au>Wang, Yajuan</au><au>Liu, Junlu</au><au>Nan, Jing</au><au>Liu, Ting</au><au>Xu, Haiyan</au><au>Qi, Songtao</au><au>Huang, Guanglong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2024-11-11</date><risdate>2024</risdate><volume>26</volume><issue>Supplement_8</issue><spage>viii257</spage><epage>viii258</epage><pages>viii257-viii258</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract OBJECTIVE Tumour-treating fields (TTFields) have changed the first-line clinical practice of glioblastoma worldwide due to their promising therapeutic efficacy. The aim of this study was to investigate the clinical efficacy of TTFields therapy for HGG in Nanfang Hospital, China. In 2023 ASNO we reported PFS.Now we reporte update about OS from our single center study. METHODS From January 2019 to December 2022, a total of 25 patients with newly diagnosed HGG (ndHGG) treated with TTFields were retrospectively included in our study. Among these patients, 9 patients received concurrent radiochemotherapy in combination with TTFields and 16 patients received non-concurrent chemoradiotherapy in combination with TTFields. The primary endpoint of the study was mPFS and mOS (Kaplan-Meier method used to estimate PFS and OS survival curves). Secondary endpoint was the influences about KPS score in PFS and OS. RESULTS The 25 ndHGG patients treated with TTFields included nine males and sixteen females with a mean age of 47.1 years (12-68). Gross total resection (GTR) was performed in eighteen patients. Twenty-one patients were IDH wild type, eleven patients showed methylation of the MGMT promoter. Followed up until January 2024, the median PFS was 13.3 months [95% CI: 11.33-15.2] with TTFields combined and 4.0 months (95% CI, 3.8-4.4) without TTFields treatment in EF-14.Median OS was 26.53 months [95% CI:19.47-33.57] with TTFields and 16.0 months (95% CI, 3.8-4.4) control in EF-14. In the KPS stratification, OS was 27.5 months (95% CI: 22.95-32.1) vs 4.3 months (95% CI: 0-11.2), p=0.0001. The OS of patients with concurrent chemoradiotherapy combined with TTFields vs. without concurrent chemoradiotherapy combined with TTFields was 26.5 months (95% CI: 24.33-28.7) vs 21.2 (95% CI: 3.1-39.3) months, p=0.59. CONCLUSIONS TTFields therapy is an effective treatment for HGG. In this study the addition of TTFields resulted in a statistically significant improvement in PFS and OS.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noae165.1019</doi></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii257-viii258
issn 1522-8517
1523-5866
language eng
recordid cdi_crossref_primary_10_1093_neuonc_noae165_1019
source Oxford Journals - Connect here FIRST to enable access
title QLTI-04. UPDATE ON HIGH-GRADE GLIOMA PATIENTS TREATED WITH TTFIELDS FROM NANFANG HOSPITAL IN CHINA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A41%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=QLTI-04.%20UPDATE%20ON%20HIGH-GRADE%20GLIOMA%20PATIENTS%20TREATED%20WITH%20TTFIELDS%20FROM%20NANFANG%20HOSPITAL%20IN%20CHINA&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Zheng,%20Haojie&rft.date=2024-11-11&rft.volume=26&rft.issue=Supplement_8&rft.spage=viii257&rft.epage=viii258&rft.pages=viii257-viii258&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae165.1019&rft_dat=%3Coup_cross%3E10.1093/neuonc/noae165.1019%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noae165.1019&rfr_iscdi=true